European Cytokine Network

, Volume 26, Issue 2, pp 38–45 | Cite as

Arjunolic acid protects against DNCB-induced atopic dermatitis-like symptoms in mice by restoring a normal cytokine balance

  • Abdullah Alyoussef
Research Article



Atopic dermatitis (AD) is a chronically relapsing, pruritic, eczematous skin disorder accompanying allergic inflammation. AD is triggered by oxidative stress and immune imbalance. The effect of oral arjunolic acid (AA) on 2,4-dinitrochlorobenzene (DNCB)-induced atopic dermatitis in mice was investigated.


Repeated epicutaneous application of DNCB to the ear and shaved dorsal skin of mice was performed to induce AD-like symptoms and skin lesions: 250mg/kg AA was given orally for three weeks to assess its anti-pruritic effects. Serum levels of tumor necrosis factor (TNF)-α, interleukin (IL)-4, IL-6, IL-10, immunoglobulin (Ig)E and caspase-3 were assessed by ELISA.


We found that AA alleviated DNCB-induced AD-like symptoms as quantified by skin lesions, dermatitis score, ear thickness and scratching behavior. Levels of reactive oxygen species in the AA group were significantly inhibited compared with those in the DNCB group. In parallel, AA blocked a DNCBinduced reduction in serum levels of IL-4 and IL-10 associated with an attenuation of DNCB-induced increases in serum TNF-α, IL-6, IgE and caspase-3.


The results indicate that AA suppresses DNCB-induced AD in mice via redox balance and immune modulation, and could be a safe clinical treatment for AD.


caspase-3 IgE IL-4/6/10 tumor necrosis factor (TNF)-α 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kim H, Kim JR, Kang H, et al. 7,8,4’-Trihydroxyisoflavone Attenuates DNCB-Induced Atopic Dermatitis-Like Symptoms in NC/Nga Mice. PloS ONE 2014; 9: e104938.PubMedCentralCrossRefPubMedGoogle Scholar
  2. 2.
    Williams H, Robertson C, Stewart A, et al. Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. J Allergy Clin Immunol 1999; 103(1 Pt 1): 125–38.CrossRefPubMedGoogle Scholar
  3. 3.
    Marsella R, Olivry T, Carlotti DN, International Task Force on Canine Atopic D. Current evidence of skin barrier dysfunction in human and canine atopic dermatitis. Vet Dermatol 2011; 22: 239–48.CrossRefPubMedGoogle Scholar
  4. 4.
    Blume-Peytavi U, Wahn U. Optimizing the treatment of atopic dermatitis in children: a reviewof the benefit/risk ratio of methylprednisolone aceponate. J Eur Acad Dermatol Venereol 2011; 25: 508–15.CrossRefPubMedGoogle Scholar
  5. 5.
    Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 2006; 54: 1–15, quiz 16-18.CrossRefPubMedGoogle Scholar
  6. 6.
    Ghosh J, Sil PC. Arjunolic acid: a new multifunctional therapeutic promise of alternative medicine. Biochimie 2013; 95: 1098–109.CrossRefPubMedGoogle Scholar
  7. 7.
    Al-Gayyar MM, Al Youssef A, Sherif IO, Shams ME, Abbas A. Protective effects of arjunolic acid against cardiac toxicity induced by oral sodium nitrite: effects on cytokine balance and apoptosis. Life Sci 2014; 111: 18–26.CrossRefGoogle Scholar
  8. 8.
    Manna P, Sil PC. Impaired redox signaling and mitochondrial uncoupling contributes vascular inflammation and cardiac dysfunction in type 1 diabetes: Protective role of arjunolic acid. Biochimie 2012; 94: 786–97.CrossRefPubMedGoogle Scholar
  9. 9.
    Sherif IO, Abdel-Aziz A, Sarhan OM. Cisplatin-Induced Testicular Toxicity in Rats: The Protective Effect of Arjunolic Acid. J Biochem Mol Toxicol 2014; 28: 515–21.CrossRefPubMedGoogle Scholar
  10. 10.
    Tayel A, Abd El Galil KH, Ebrahim MA, Ibrahim AS, El-Gayar AM, Al-Gayyar MM. Suramin inhibits hepatic tissue damage in hepatocellular carcinoma through deactivation of heparanase enzyme. Eur J Pharmacol 2014; 72: 8151–60.Google Scholar
  11. 11.
    Darweish MM, Abbas A, Ebrahim MA, Al-Gayyar MM. Chemopreventive and hepatoprotective effects of Epigallocatechin-gallate against hepatocellular carcinoma: role of heparan sulfate proteoglycans pathway. J Pharm Pharmacol 2014; 66: 1032–45.CrossRefPubMedGoogle Scholar
  12. 12.
    Beutler E, Duron O, Kelly BM. Improved method for the determination of blood glutathione. J Lab Clin Med 1963; 61: 882–8.PubMedGoogle Scholar
  13. 13.
    Boguniewicz M, Leung DY. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev 2011; 242: 233–46.PubMedCentralCrossRefPubMedGoogle Scholar
  14. 14.
    Yang MH, Ali Z, Khan IA, Khan SI. Anti-inflammatory activity of constituents isolated from Terminalia chebula. Nat Prod Commun 2014; 9: 965–8.PubMedGoogle Scholar
  15. 15.
    Hemalatha T, Pulavendran S, Balachandran C, Manohar BM, Puvanakrishnan R. Arjunolic acid: a novel phytomedicine with multifunctional therapeutic applications. Indian J Exp Biol 2010; 48: 238–47.PubMedGoogle Scholar
  16. 16.
    Sivaranjani N, Rao SV, Rajeev G. Role of reactive oxygen species and antioxidants in atopic dermatitis. J Clin Diagn Res 2013; 7: 2683–5.PubMedCentralPubMedGoogle Scholar
  17. 17.
    Bieber T. Atopic dermatitis. N Engl J Med 2008; 358: 1483–94.CrossRefPubMedGoogle Scholar
  18. 18.
    Peroni DG, Bodini A, Corradi M, Coghi A, Boner AL, Piacentini GL. Markers of oxidative stress are increased in exhaled breath condensates of children with atopic dermatitis. Br J Dermatol 2012; 166: 839–43.CrossRefPubMedGoogle Scholar
  19. 19.
    Ott H, Stanzel S, Ocklenburg C, Merk HF, Baron JM, Lehmann S. Total serum IgE as a parameter to differentiate between intrinsic and extrinsic atopic dermatitis in children. Acta Derm Venereol 2009; 89: 257–61.CrossRefPubMedGoogle Scholar
  20. 20.
    Behniafard N, Gharagozlou M, Farhadi E, et al. TNF-alpha single nucleotide polymorphisms in atopic dermatitis. Eur Cytokine Netw 2012; 23: 163–5.PubMedGoogle Scholar
  21. 21.
    Auriemma M, Vianale G, Amerio P, Reale M. Cytokines and T cells in atopic dermatitis. Eur Cytokine Netw 2013; 24: 37–44.PubMedGoogle Scholar
  22. 22.
    Arshad SH, Holgate S. The role of IgE in allergen-induced inflammation and the potential for intervention with a humanized monoclonal anti-IgE antibody. Clin Exp Allergy 2001; 31: 1344–51.CrossRefPubMedGoogle Scholar
  23. 23.
    Guo LY, Hung TM, Bae KH, et al. Anti-inflammatory effects of schisandrin isolated from the fruit of Schisandra chinensis Baill. Eur J Pharmacol 2008; 591: 293–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Pal S, Pal PB, Das J, Sil PC. Involvement of both intrinsic and extrinsic pathways in hepatoprotection of arjunolic acid against cadmium induced acute damage in vitro. Toxicology 2011; 283: 129–39.CrossRefPubMedGoogle Scholar
  25. 25.
    Ghosh J, Das J, Manna P, Sil PC. Acetaminophen induced renal injury via oxidative stress and TNF-alpha production: therapeutic potential of arjunolic acid. Toxicology 2010; 268: 8–18.CrossRefPubMedGoogle Scholar

Copyright information

© John Libbey Eurotext 2015

Authors and Affiliations

  1. 1.Dept. of Internal Medicine (Dermatology), Faculty of MedicineUniversity of TabukTabukSaudi Arabia

Personalised recommendations